JP2022544714A5 - - Google Patents

Info

Publication number
JP2022544714A5
JP2022544714A5 JP2022512349A JP2022512349A JP2022544714A5 JP 2022544714 A5 JP2022544714 A5 JP 2022544714A5 JP 2022512349 A JP2022512349 A JP 2022512349A JP 2022512349 A JP2022512349 A JP 2022512349A JP 2022544714 A5 JP2022544714 A5 JP 2022544714A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
tautomer
acceptable salt
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022512349A
Other languages
English (en)
Japanese (ja)
Other versions
JP7646632B2 (ja
JP2022544714A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047467 external-priority patent/WO2021041237A1/en
Publication of JP2022544714A publication Critical patent/JP2022544714A/ja
Publication of JP2022544714A5 publication Critical patent/JP2022544714A5/ja
Priority to JP2025034294A priority Critical patent/JP2025106242A/ja
Application granted granted Critical
Publication of JP7646632B2 publication Critical patent/JP7646632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022512349A 2019-08-23 2020-08-21 甲状腺ホルモン受容体ベータアゴニスト化合物 Active JP7646632B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025034294A JP2025106242A (ja) 2019-08-23 2025-03-05 甲状腺ホルモン受容体ベータアゴニスト化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962891078P 2019-08-23 2019-08-23
US62/891,078 2019-08-23
US202062967943P 2020-01-30 2020-01-30
US62/967,943 2020-01-30
PCT/US2020/047467 WO2021041237A1 (en) 2019-08-23 2020-08-21 Thyroid hormone receptor beta agonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025034294A Division JP2025106242A (ja) 2019-08-23 2025-03-05 甲状腺ホルモン受容体ベータアゴニスト化合物

Publications (3)

Publication Number Publication Date
JP2022544714A JP2022544714A (ja) 2022-10-20
JP2022544714A5 true JP2022544714A5 (cg-RX-API-DMAC7.html) 2023-08-28
JP7646632B2 JP7646632B2 (ja) 2025-03-17

Family

ID=74684314

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022512349A Active JP7646632B2 (ja) 2019-08-23 2020-08-21 甲状腺ホルモン受容体ベータアゴニスト化合物
JP2025034294A Pending JP2025106242A (ja) 2019-08-23 2025-03-05 甲状腺ホルモン受容体ベータアゴニスト化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025034294A Pending JP2025106242A (ja) 2019-08-23 2025-03-05 甲状腺ホルモン受容体ベータアゴニスト化合物

Country Status (7)

Country Link
US (2) US12528791B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017875A4 (cg-RX-API-DMAC7.html)
JP (2) JP7646632B2 (cg-RX-API-DMAC7.html)
CN (1) CN114430743A (cg-RX-API-DMAC7.html)
AU (1) AU2020336272B2 (cg-RX-API-DMAC7.html)
CA (1) CA3154488A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021041237A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4178672A1 (en) 2020-07-10 2023-05-17 Aligos Therapeutics, Inc. MODULATORS OF THR-ß AND METHODS OF USE THEREOF
WO2022037617A1 (zh) * 2020-08-19 2022-02-24 成都凡诺西生物医药科技有限公司 腈代三嗪类衍生物及其制备方法和应用
JP2024510935A (ja) * 2021-03-03 2024-03-12 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
US20240239761A1 (en) * 2021-03-19 2024-07-18 Medshine Discovery Inc. Bicyclic phenol compounds and use thereof
CN116940566A (zh) * 2021-03-19 2023-10-24 南京明德新药研发有限公司 双环吡啶酮类化合物及其应用
TW202313615A (zh) * 2021-05-21 2023-04-01 大陸商深圳微芯生物科技股份有限公司 一種雜環化合物及其應用
TWI910297B (zh) * 2021-12-24 2026-01-01 大陸商廣東東陽光藥業股份有限公司 一種作為甲狀腺激素β受體激動劑的化合物及其用途
CN113979963B (zh) * 2021-12-24 2022-03-11 凯思凯旭(上海)医药科技有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases
CN120923503A (zh) * 2025-10-10 2025-11-11 吉斯凯(苏州)制药有限公司 具有杂环结构的化合物、THRβ受体激动剂及用途

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197307A (en) 1977-04-12 1980-04-08 Ciba-Geigy Corporation 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents
EP0377903A3 (de) 1989-01-09 1991-07-17 Bayer Ag Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
GB0015205D0 (en) * 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
WO2002051805A1 (de) 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
CA2473162A1 (en) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
GB0608724D0 (en) 2006-05-03 2006-06-14 Karobio Ab Novel Pharmaceutical Compositions
WO2007132475A1 (en) 2006-05-15 2007-11-22 Cadila Healthcare Limited Selective tr-beta 1 agonist
GB0610322D0 (en) * 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
WO2008130637A1 (en) 2007-04-18 2008-10-30 New York University Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
SI2170403T1 (sl) 2007-06-27 2014-07-31 Quark Pharmaceuticals, Inc. Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
FR2933979B1 (fr) 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
KR101396606B1 (ko) 2009-04-20 2014-05-16 미쓰비시 타나베 파마 코퍼레이션 신규 갑상선 호르몬 β 수용체 작동약
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
EA023521B1 (ru) 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102898377B (zh) 2012-02-14 2016-01-20 南京圣和药业股份有限公司 一类酞嗪酮衍生物及其用途
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
CN105477636B (zh) 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ROR-γ調節劑
MX2018011813A (es) 2016-03-28 2019-01-24 Intercept Pharmaceuticals Inc Medicina obtenida mediante la combinacion de agonista fxr y arb.
PL3435996T3 (pl) 2016-03-31 2025-07-28 Genfit Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych
MX2018014024A (es) 2016-05-25 2019-08-29 Akarna Therapeutics Ltd Terapias de combinación con moduladores del receptor x farnesoide (fxr).
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
CA3041169A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
WO2018103624A1 (zh) 2016-12-06 2018-06-14 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Pparアゴニストとfxrアゴニストとの組合せ
SG11201907673YA (en) 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CA3058542A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
WO2018208707A1 (en) 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
SG11202000748TA (en) 2017-08-25 2020-03-30 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
WO2019053235A1 (en) 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
EP3684954B1 (en) 2017-09-18 2025-11-26 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
US11168079B2 (en) 2017-11-01 2021-11-09 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
US20200340060A1 (en) 2017-11-13 2020-10-29 Gilead Sciences, Inc. Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
CN109574995B (zh) * 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
KR20210002573A (ko) 2018-04-24 2021-01-08 주식회사 피에이치파마 간 질환에 호중구 엘라스타제 저해제의 사용
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
WO2020041741A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
EP3844156A4 (en) 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISEASES
NZ773110A (en) 2018-09-18 2024-11-29 Terns Inc Compounds for treating certain leukemias
US20220047553A1 (en) 2018-09-18 2022-02-17 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN119552152A (zh) 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
CN119431265A (zh) * 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
WO2020228577A1 (zh) 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
TW202114672A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 使用fxr促效劑的肝臟疾病之組合治療
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021121210A1 (zh) 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
WO2021231646A1 (en) 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
WO2021231644A1 (en) 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
US20220135540A1 (en) 2020-10-15 2022-05-05 Eli Lilly And Company Polymorphs of an fxr agonist
CN114437034A (zh) 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
JP2024510935A (ja) 2021-03-03 2024-03-12 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
US20240239761A1 (en) 2021-03-19 2024-07-18 Medshine Discovery Inc. Bicyclic phenol compounds and use thereof
MX2024005647A (es) 2021-11-11 2024-05-24 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-\03b2.
AU2022387121A1 (en) 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
US20230181583A1 (en) 2021-11-11 2023-06-15 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor
WO2023220404A1 (en) 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica

Similar Documents

Publication Publication Date Title
JP2024050527A5 (cg-RX-API-DMAC7.html)
JP2022548250A5 (cg-RX-API-DMAC7.html)
JP2021535207A5 (cg-RX-API-DMAC7.html)
JP2022512482A5 (cg-RX-API-DMAC7.html)
JP2022504620A5 (cg-RX-API-DMAC7.html)
WO2018013597A4 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP2019034943A5 (cg-RX-API-DMAC7.html)
JP2021523221A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2022550640A5 (cg-RX-API-DMAC7.html)
JP2020521766A5 (cg-RX-API-DMAC7.html)
JP2016517417A5 (cg-RX-API-DMAC7.html)
JP2019510787A5 (cg-RX-API-DMAC7.html)
JP2024512154A5 (cg-RX-API-DMAC7.html)
JP2019522055A5 (cg-RX-API-DMAC7.html)
JP2022501429A5 (cg-RX-API-DMAC7.html)
JP2016500661A5 (cg-RX-API-DMAC7.html)
JP2018526399A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2020521767A5 (cg-RX-API-DMAC7.html)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
WO2006019962B1 (en) Compositions and methods for treatment of colitis
RU2010119487A (ru) Пиримидилиндолиновое соединение
JP2008505171A5 (cg-RX-API-DMAC7.html)
JP2017529389A5 (cg-RX-API-DMAC7.html)